Pluri Inc.
PLUR
Rank in Stocks
#27293
Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology... Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology company dedicated to advancing placenta-derived cell therapies. Its primary goal is to address a spectrum of health issues, including inflammatory conditions, muscle damage, and blood disorders. The company's core development involves placental expanded (PLX) cell products. A leading candidate, PLX-PAD, is currently in a Phase III clinical trial to improve muscle recovery following hip fracture surgery. It is also undergoing a Phase I/II trial, in partnership with Tel Aviv Sourasky Medical Center, for the treatment of steroid-refractory graft versus host disease. Furthermore, PLX-PAD has successfully completed a Phase II clinical trial for acute respiratory distress syndrome linked to COVID-19 and a Phase I trial for patients with incomplete recovery after bone marrow transplantation. Another key product, PLX-R18, is being developed to aid in the recovery of blood cell production following hematopoietic cell transplantation. Pluri is also collaborating with the National Institutes of Health and the U.S. Department of Defense to create a therapeutic solution for acute radiation syndrome. The company, formerly known as Pluristem Therapeutics Inc., adopted its current name, Pluri Inc., in July 2022.
Share Price
$1.18
Last synced: 2026-11-09
Market Cap
$15.80M
Change (1 day)
-4.48%
Change (1 year)
-71.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pluri Inc. (PLUR)
Category
Healthcare
Operating Margin for Pluri Inc. (PLUR)
Operating Margin as of November 2026 TTM: -2,455.91%
According to Pluri Inc.'s latest financial reports, its current operating margin (TTM) is -2,455.91%. At the end of 2025 the company had an operating margin of -1,659.88%.
Operating Margin history for Pluri Inc. from 2002 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,455.91% | 47.96% |
| 2025 | -1,659.88% | -75.58% |
| 2024 | -6,796.93% | -28.40% |
| 2023 | -9,493.38% | -46.59% |
| 2022 | -17,774.79% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -128,156.52% | 94.77% |
| 2019 | -65,800.00% | -2.46% |
| 2018 | -67,462.00% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -819.07% | -87.71% |
| 2015 | -6,666.75% | -9.27% |
| 2014 | -7,348.28% | 124.52% |
| 2013 | -3,272.90% | 55.90% |
| 2012 | -2,099.30% | -417.71% |
| 2011 | 660.76% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.94% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pluri Inc.'s operating margin
What is Pluri Inc.'s operating margin?
Pluri Inc.'s operating margin is -2,455.91%, as of Nov 2026.
What was Pluri Inc.'s operating margin in 2025?
In 2025, Pluri Inc.'s operating margin was -1,659.88%, compared with -6,796.93% in 2024.
How has Pluri Inc.'s operating margin changed since 2020?
From 2020 to 2025, Pluri Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2020 (-128,156.52%).
How does Pluri Inc.'s operating margin compare with similar companies?
Pluri Inc.'s operating margin (-2,455.91%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.